Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

162.21 -1.47 (-0.90%)
Streaming Delayed Price Updated: 12:52 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street ↗
 
Via Benzinga
News headline image
3 Cash-Producing Stocks We Approach with Caution
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts ↗
 
Via Benzinga
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
News headline image
SciSparc And AutoMax Call Off Merger ↗
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
News headline image
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
News headline image
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 5 Analysts Discuss Jazz Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for... 
Via StockStory
Topics Artificial Intelligence
News headline image
Jazz (JAZZ) Q2 Revenue Rises 2% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Recognized as a Decent Value Stock with Strong Fundamentals ↗
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential. 
Via Chartmill
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
News headline image
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Reports Q2 2025 Earnings Miss and Leadership Transition ↗
Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger. 
Via Chartmill
Topics Earnings
News headline image
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Where Jazz Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
JAZZ Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and decent growth, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
News headline image
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz ↗
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
News headline image
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors. 
Via Chartmill
News headline image
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
News headline image
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.